Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 63

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 63
---
acterial Activity. The antibacterial spectrum of Mupirocin is well                     
 studied. Mupirocin is registered as a topical ointment (Bactroban™ by GlaxoSmithKlein).              
 Mupirocin is known to be highly effective against staphylococci, streptococci, certain Gram-negative 
 bacilli, including N. gonorrhoea and a broad range of Gram-positive bacteria. Mupirocin’s            
 activity is enhanced at acidic pH levels and is not significantly influenced by inoculum             
 size, although its effectiveness decreases in serum due to high protein binding (95%). Its           
 primary mechanism involves inhibiting RNA and protein synthesis by targeting the isoleucine-binding  
 site on the isoleucyl-transfer-RNA synthetase enzyme in bacteria. This unique mode of action,        
 different from other antibiotics, reduces the likelihood of cross-resistance.                        |

Nano-Mupirocin has shown in vitroeffectiveness against a wide range of bacteria, including those that are high on the WHO and CDC priority lists for new antibiotics, such as methicillin-resistant Staphylococcus aureus(MRSA), vancomycin-resistant Enterococcus faecium(VRE), and cephalosporin-resistant Neisseria gonorrhoeae.

| ● | No                                                                                          
 cross-resistance. Nano-Mupirocin has shown no observable cross-resistance with commercially 
 available antibiotics, meaning that it can be effective against bacteria that are resistant 
 to other classes of antibiotics. This is because Mupirocin has a unique mode of action that 
 does not interfere with the mechanisms of resistance of other antibiotics.                  |

| ● | Enhanced                                                                                           
 uptake. Nano-Mupirocin exhibits superior uptake and activity on phagocytic cells, such             
 as macrophages and neutrophils, which are involved in the immune response to bacterial infections. 
 Nano-Mupirocin can enhance the ability of these cells to kill bacteria and clear the infection.    |

| ● | Proven                                                                                         
 pre-clinical safety profile. Nano-Mupirocin has maintained an excellent safety record          
 in preclinical studies. Nano-Mupirocin does not contain any foreign genetic material, such     
 as mRNA or DNA, that can trigger innate immune responses or interfere with cellular functions. 
 Nano-Mupirocin also does not contain any adjuvants, preservatives, or stabilizers, that can    
 cause unwanted effects or allergic reactions.                                                  |

| ● |